Emergent BioSolutions Inc
EBS12.430USD
-0.200-1.58%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
655.06MMarket Cap
8.75P/E TTM
More Details of Emergent BioSolutions Inc Company
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
Emergent BioSolutions Inc Info
Ticker SymbolEBS
Company nameEmergent BioSolutions Inc
IPO dateNov 15, 2006
CEOPapa (Joseph C)
Number of employees900
Security typeOrdinary Share
Fiscal year-endNov 15
Address300 Professional Dr
CityGAITHERSBURG
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code20879
Phone12406313200
Websitehttps://emergentbiosolutions.com/
Ticker SymbolEBS
IPO dateNov 15, 2006
CEOPapa (Joseph C)
Company Executives of Emergent BioSolutions Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Ms. Jessica Perl
Ms. Jessica Perl
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
68.39K
+1061.66%
Mr. Marvin L. White
Mr. Marvin L. White
Independent Director
Independent Director
68.25K
+101.64%
Mr. Keith A. Katkin, CPA
Mr. Keith A. Katkin, CPA
Independent Director
Independent Director
66.14K
-10.60%
Mr. William Hartzel
Mr. William Hartzel
Senior Vice President - Manufacturing and Bioservices
Senior Vice President - Manufacturing and Bioservices
62.55K
-0.97%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joseph C. (Joe) Papa
Mr. Joseph C. (Joe) Papa
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
342.50K
+21.24%
Mr. Richard S. (Rich) Lindahl
Mr. Richard S. (Rich) Lindahl
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
196.50K
-2.48%
Dr. Zsolt Harsanyi, Ph.D.
Dr. Zsolt Harsanyi, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
103.49K
+49.80%
Dr. Simon C Lowry, M.D.
Dr. Simon C Lowry, M.D.
Chief Medical Officer, Head of Research and Development
Chief Medical Officer, Head of Research and Development
91.98K
+211.99%
Ms. Coleen Glessner
Ms. Coleen Glessner
Executive Vice President - Quality and Ethics and Compliance
Executive Vice President - Quality and Ethics and Compliance
90.86K
-25.20%
Mr. Ronald B. Richard
Mr. Ronald B. Richard
Independent Director
Independent Director
78.17K
-8.33%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
By RegionUSD
Name
Revenue
Proportion
Non-U.S Government
83.10M
58.98%
U.S.Government
57.80M
41.02%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Commercial Product sales
67.50M
47.91%
MCM Product sales
58.40M
41.45%
Contracts and grants
15.00M
10.65%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
Other
72.56%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.43%
The Vanguard Group, Inc.
6.74%
State Street Investment Management (US)
4.66%
American Century Investment Management, Inc.
4.54%
Dimensional Fund Advisors, L.P.
4.08%
Other
72.56%
Shareholder Types
Shareholders
Proportion
Investment Advisor
34.85%
Investment Advisor/Hedge Fund
30.34%
Hedge Fund
7.25%
Individual Investor
2.97%
Research Firm
1.58%
Pension Fund
1.08%
Bank and Trust
0.83%
Sovereign Wealth Fund
0.18%
Family Office
0.07%
Other
20.85%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
378
39.86M
83.14%
+128.30K
2025Q3
417
39.73M
84.87%
+2.04M
2025Q2
439
37.58M
87.40%
+1.14M
2025Q1
454
36.44M
84.55%
-9.64M
2024Q4
461
35.04M
82.31%
+2.84M
2024Q3
467
32.21M
81.37%
+1.29M
2024Q2
485
30.86M
99.60%
-5.54M
2024Q1
494
36.44M
103.37%
-17.72M
2023Q4
512
41.89M
103.68%
-1.06M
2023Q3
563
42.52M
113.85%
-6.21M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
3.83M
7.18%
+2.25M
+141.83%
Jun 30, 2025
The Vanguard Group, Inc.
3.58M
6.72%
+370.21K
+11.52%
Jun 30, 2025
State Street Investment Management (US)
1.74M
3.26%
+30.01K
+1.75%
Jun 30, 2025
American Century Investment Management, Inc.
2.29M
4.3%
-5.46K
-0.24%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
1.85M
3.47%
+252.40K
+15.81%
Jun 30, 2025
Palisade Capital Management, LLC
1.10M
2.06%
-41.83K
-3.66%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
1.11M
2.07%
+521.91K
+89.48%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
2.4%
+666.71K
+108.89%
Jun 30, 2025
Acadian Asset Management LLC
974.59K
1.83%
+141.27K
+16.95%
Jun 30, 2025
Connor, Clark & Lunn Investment Management Ltd.
986.67K
1.85%
+55.05K
+5.91%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
AdvisorShares Insider Advantage ETF
0.97%
Royce Quant Small-Cap Quality Value ETF
0.41%
State Street SPDR S&P Biotech ETF
0.28%
Federated Hermes MDT Small Cap Core ETF
0.23%
Harbor Human Capital Factor US Small Cap ETF
0.19%
Direxion Daily S&P Biotech Bull 3X Shares
0.18%
Pacer US Small Cap Cash Cows ETF
0.16%
Invesco RAFI US 1500 Small-Mid ETF
0.15%
Avantis US Small Cap Value ETF
0.14%
iShares Micro-Cap ETF
0.13%
View more
AdvisorShares Insider Advantage ETF
Proportion0.97%
Royce Quant Small-Cap Quality Value ETF
Proportion0.41%
State Street SPDR S&P Biotech ETF
Proportion0.28%
Federated Hermes MDT Small Cap Core ETF
Proportion0.23%
Harbor Human Capital Factor US Small Cap ETF
Proportion0.19%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.18%
Pacer US Small Cap Cash Cows ETF
Proportion0.16%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.15%
Avantis US Small Cap Value ETF
Proportion0.14%
iShares Micro-Cap ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Emergent BioSolutions Inc?
The top five shareholders of Emergent BioSolutions Inc are:
BlackRock Institutional Trust Company, N.A. holds 3.83M shares, accounting for 7.18% of the total shares.
The Vanguard Group, Inc. holds 3.58M shares, accounting for 6.72% of the total shares.
State Street Investment Management (US) holds 1.74M shares, accounting for 3.26% of the total shares.
American Century Investment Management, Inc. holds 2.29M shares, accounting for 4.30% of the total shares.
Dimensional Fund Advisors, L.P. holds 1.85M shares, accounting for 3.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.83M shares, accounting for 7.18% of the total shares.
The Vanguard Group, Inc. holds 3.58M shares, accounting for 6.72% of the total shares.
State Street Investment Management (US) holds 1.74M shares, accounting for 3.26% of the total shares.
American Century Investment Management, Inc. holds 2.29M shares, accounting for 4.30% of the total shares.
Dimensional Fund Advisors, L.P. holds 1.85M shares, accounting for 3.47% of the total shares.
What are the top three shareholder types of Emergent BioSolutions Inc?
The top three shareholder types of Emergent BioSolutions Inc are:
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
State Street Investment Management (US)
How many institutions hold shares of Emergent BioSolutions Inc (EBS)?
As of 2025Q4, 378 institutions hold shares of Emergent BioSolutions Inc, with a combined market value of approximately 39.86M, accounting for 83.14% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.74%.
What is the biggest source of revenue for Emergent BioSolutions Inc?
In FY2025Q2, the Commercial Product sales business generated the highest revenue for Emergent BioSolutions Inc, amounting to 67.50M and accounting for 47.91% of total revenue.
